CEPI

The state of the fight: 

Moderna pledged permanently to forgo enforcement of its Covid-19 vaccine patents for shots made “in or for” 92 LMICs.
  Aspen Pharmacare will market an Aspen-branded version of J&J’s vaccine in Africa.
  Fluvoxamine reduced the risk of Covid-19 hospitalization and clinical deterioration by 31% in a meta-analysis.   BOOSTERS

 
A WHO technical advisory group now “strongly supports urgent and broad access” to Covid-19 booster doses…

Neutralizing antibody titers produced by Valneva’s live attenuated, single-dose chikungunya vaccine candidate (VLA1553) held up in over 96% of trial participants after six months, the company announced Tuesday, citing a final analysis of Phase 3 data.

Seroprotection levels at the one-month mark confirmed topline data the French biotech shared in 2021: the Coalition for Epidemic Preparedness Innovations-backed shot generated neutralizing antibodies in nearly 99% of participants, the…

The Coalition for Epidemic Preparedness Innovations locked up over $1.5 billion this week as countries, NGOs and other donors made commitments at the Global Pandemic Preparedness Summit in London.

Pledged funds will back CEPI’s $3.5 billion plan to boost global R&D and manufacturing over the next five years and “compress vaccine development timelines to 100 days,” according to CEPI’s Tuesday press release.

The state of the fight: 

Sanofi and GSK’s vaccine candidate demonstrated 58% efficacy against symptomatic Covid-19 in Phase 3.
  Hetero Pharma’s generic version of Merck’s molnupiravir reduced the risk of hospitalization by over 65%.
  Britain and Japan pledged a combined $514 million to CEPI’s pandemic preparedness plan.   AUTHORIZED VACCINES

 
The U.S. FDA lifted its clinical hold on Bharat Biotech’s Covaxin, clearing the way for the inactivated vaccine to…

Public Health Vaccines (PHV) has launched a Phase 1 trial of its PHV02 single-dose, recombinant vesicular stomatitis virus (rVSV)-based vaccine candidate against Nipah virus, the biotech announced Wednesday.

PHV is developing the shot with fellow Massachusetts-based company Crozet BioPharma. In 2019, the project secured up to $43.6 million in funding from the Coalition for Epidemic Preparedness Innovations to bring it through Phase 2.

Valneva has launched an additional Phase 3 trial in Brazil of its VLA1553 live attenuated, single-dose chikungunya vaccine, the French company announced Monday.

The announcement follows previous Phase 3 data showing the Coalition for Epidemic Preparedness Innovations (CEPI)-backed shot produced neutralizing antibodies in 98.5% of participants and was well-tolerated in adults.

The new study tests the jab in adolescents ages 12 to 17 and, if successful, will support licensure in…

The state of the fight: 

Moderna and Pfizer/BioNTech launched trials of Omicron-specific vaccine candidates.
  India fully approved SII’s Covishield and Bharat Biotech’s Covaxin shots.
  CEPI tapped BioNet to develop a “variant-proof” pan-coronavirus mRNA-based vaccine.

AUTHORIZED VACCINES  

New data on rates of myocarditis following mRNA-based vaccination trickled in this week, highlighting an increased risk of the heart inflammation side effect in young men…

The state of the fight: 

African vaccine production advanced on multiple fronts, including the opening of a new manufacturing plant in South Africa.
  The COVAX AMC seeks an additional $5.2 billion this year.
  Merck will supply UNICEF with up to 3 million courses of molnupiravir in the first half of 2022.

AUTHORIZED VACCINES  

The Chilean health ministry released data on the Sinovac jab’s effectiveness in children. In kids ages 6-11, the topline numbers…

The state of the fight: 

India granted Biological E’s Corbevax—a low-cost, patent-free vaccine—its first regulatory authorization.
  A J&J booster was 85% effective against hospitalization in South Africa during the Omicron wave.
  India authorized molnupiravir but omitted the antiviral from its recommended clinical protocol on safety concerns.

 

AUTHORIZED VACCINES

 
Bharat Biotech’s Covaxin generated “superior antibody responses” in children…

The state of the fight: 

Oral antivirals from Pfizer and Merck notched U.S. FDA authorizations.
  Earlier use of remdesivir cut the risk of death or hospitalization by 87% in a new study.
  The Novavax vaccine secured a second WHO Emergency Use Listing.

AUTHORIZED VACCINES  

The AstraZeneca/Oxford vaccine starts waning in protection against serious illness within three months of the second dose, according to cohort studies in Brazil and Scotland published…